Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
River Oaks Capital Whit Huguley | “Ascent Industries is a specialty chemical manufacturer. It is the fifth largest position in our fund and has a $135m market cap. Ascent trades at a $135 million market cap; net of $28 million in cash, enterprise value is ~$107 million. The company operates a 'chemicals-as-a-service' model, serving as a one-stop shop for small and mid-sized customers in a fragmented niche market largely ignored by major players. CEO Bryan Kitchen, brought on in 2023, previously led a comparable turnaround from an $8 million EBITDA loss to $36 million in EBITDA over 4.5 years, and brought his prior core team with him to Ascent. Operating at just ~45% capacity, Ascent can scale revenue from ~$80 million to over $130 million with minimal capex, while gross margins expand toward their 35% target – implying $20-25 million of projected EBITDA and a natural acquisition target. Bryan and his team are buying back 12–15% of shares annually while pursuing this plan, effectively 'creating its own catalyst.' Bryan's compensation package does not vest until the stock reaches $28–29 per share, closely aligning his incentives with shareholders. Having gotten to know him well, I consider him the A+ CEO we are looking for who can dominate this niche specialty chemical market. Under Bryan and his team, the focus has shifted to 'product sales': proprietary formulations built around specific customer needs, encompassing formulation, blending, packaging, logistics, and regulatory compliance. Bryan and his team refer to the strategy as 'chemicals-as-a-service.' These sales are stickier, less cyclical, and higher margin than toll manufacturing. Organic revenue grew ~28% year-over-year to a $100 million+ run-rate. The active selling pipeline stands at ~$140 million; at a conservative 20% conversion rate, this implies ~$30 million of incremental revenue. Including the Midwest Graphics acquisition (~$11 million in pre-acquisition revenue) and its growth potential, revenue could conservatively exceed $130 million within 1–2 years. 'Product sales' currently represent ~45% of revenue and are expected to rise to 65–80% as revenue increases. Margins were 22% in Q2 2026, below the ~28% high-water mark reached in Q3 2025 – reflecting the pricing and speed concessions required to onboard recent 'product-sales' wins. Management expects $3–5 million of incremental gross margin from optimizing these contracts. Ascent repurchased $6.9 million of shares in H1 2026 (following 7–8% of shares repurchased in 2025). I expect them to continue to buyback 12–15%+ of outstanding shares annually. In May, Bryan and his team acquired Midwest Graphics for $14 million. Midwest Graphics is a specialty chemical formulator of coatings for regulated packaging, foodservice, and consumer applications, previously family-owned for roughly three decades. The deal fits nicely with Ascent's chemicals-as-a-service strategy, adding a customer-embedded, formulation-driven business that had struggled to win larger accounts as a standalone small company. Midwest's key asset is an APEO-free coating technology for paper plates — the only commercial solution of its kind, developed over 2–3 years. Pre-acquisition, Midwest generated ~$11 million in revenue at ~25% gross margin and $2 million EBITDA; a new plate-coating contract alone could conservatively double revenue, with $20 million+ of additional upside from adjacent applications. The market appears to be underappreciating the upside potential of Midwest Graphics. On a Q2 2026 run-rate basis, free cash flow to equity is modest at ~$5 million (pre-Midwest Graphics) – a ~5% yield (~20x P/E). Including Midwest Graphics and a 20% conversion of the $140 million pipeline, revenue could reach $130 million+ within roughly a year. If margin and mix targets are achieved, this implies $18–20 million of free cash flow to equity – a 16–18% yield (~6x P/E) – with capacity still available at existing facilities. Ascent's ~$28 million cash balance provides ongoing flexibility for continued buybacks (12–15% of shares annually) and further accretive M&A. Bryan and his team have positioned the company well for a potential future sale, while returning capital to shareholders in the meantime.” | BULL | Q2 2026 Aug 31, 2026 | View Pitch |
Merion Road Capital Aaron Sallen | “During the quarter I built a position in Ascent Industries (“ACNT”). ACNT is a small specialty chemicals company that is transforming from an over-levered conglomerate into a pure-play with a pristine balance. In early 2024 the company revamped its management team with the election of a new CEO & CFO. Since then, ACNT has sold off its tubular steel assets, thereby eliminating $70m of debt and leaving the company with almost $60m of cash. Management stabilized operations by raising prices and exiting unprofitable business, improving gross profit materially despite lower revenue. With facilities running at roughly 50% utilization, the company can scale revenue significantly with minimal capex. Operating leverage, proprietary product mix, and a recent $10m+ annualized program win support the case for EBITDA margins expanding to greater than 20%. BSD Analysis: Ascent Industries is undergoing a strategic pivot in 2026, shifting its focus from cyclical tubular products toward higher-margin specialty chemicals and industrial applications. The company's specialty chemicals segment is capturing new growth in the oil and gas and personal care sectors, leveraging its vertically integrated manufacturing model to protect margins. For 2026, the investment narrative is centered on a balance sheet cleanup and a refined capital allocation strategy intended to unlock the intrinsic value of its underappreciated assets. While the firm's market capitalization remains relatively small, its presence in high-barrier niches such as pulp and paper and agricultural chemicals provides a resilient cash flow base. Management is prioritizing operational efficiency and footprint optimization to counter potential volatility in raw material costs. For value-oriented investors, Ascent offers a "sum-of-the-parts" turnaround play with significant upside as it demonstrates consistent profitability in its core chemical business.” | BULL | Q4 2025 Jan 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
